Czech National Bank Has $4.56 Million Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Czech National Bank grew its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,164 shares of the medical equipment provider’s stock after purchasing an additional 1,678 shares during the period. Czech National Bank’s holdings in Zimmer Biomet were worth $4,559,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of ZBH. Wealth Enhancement Advisory Services LLC grew its position in Zimmer Biomet by 8.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 15,845 shares of the medical equipment provider’s stock valued at $1,710,000 after purchasing an additional 1,173 shares in the last quarter. ORG Partners LLC raised its stake in Zimmer Biomet by 14,497.5% during the 4th quarter. ORG Partners LLC now owns 5,839 shares of the medical equipment provider’s stock valued at $617,000 after purchasing an additional 5,799 shares during the last quarter. First Hawaiian Bank boosted its holdings in Zimmer Biomet by 14.0% in the 4th quarter. First Hawaiian Bank now owns 20,400 shares of the medical equipment provider’s stock valued at $2,155,000 after purchasing an additional 2,500 shares during the period. Nordea Investment Management AB increased its holdings in shares of Zimmer Biomet by 3.9% during the 4th quarter. Nordea Investment Management AB now owns 16,333 shares of the medical equipment provider’s stock worth $1,732,000 after purchasing an additional 609 shares during the period. Finally, Central Pacific Bank Trust Division raised its position in shares of Zimmer Biomet by 7.4% during the fourth quarter. Central Pacific Bank Trust Division now owns 14,525 shares of the medical equipment provider’s stock valued at $1,534,000 after buying an additional 1,000 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $106.34 on Thursday. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The business’s 50 day moving average is $107.88 and its 200-day moving average is $107.97. Zimmer Biomet Holdings, Inc. has a 1-year low of $100.67 and a 1-year high of $133.90. The firm has a market cap of $21.17 billion, a P/E ratio of 20.22, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company’s revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the business earned $1.65 earnings per share. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.90%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s payout ratio is presently 18.25%.

Analyst Ratings Changes

ZBH has been the topic of several analyst reports. Evercore ISI lowered their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Royal Bank of Canada upped their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, November 4th. Raymond James dropped their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a report on Monday, October 14th. Wells Fargo & Company increased their target price on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Finally, Oppenheimer reduced their price target on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 15th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $123.33.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.